{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:28:03Z","timestamp":1771471683348,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007343","name":"Universit\u00e0 degli Studi di Brescia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007343","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Heart failure with preserved ejection fraction (HFpEF) accounts for more than half of heart failure hospital admissions in the last years and is burdened by high mortality and poor quality of life. Providing effective management for HFpEF patients is a major unmet clinical need. Increase in left atrial pressure is the key determinant of pulmonary congestion, with consequent dyspnoea and exercise limitation. Evidence on benefits of medical treatment in HFpEF patients is limited. Thus, alternative strategies, including devices able to reduce left atrial pressure, through an interatrial communication determining a left\u2013right shunt, were developed. This review aims to summarize evidence regarding the use of percutaneous interatrial shunting devices. These devices are safe and effective in improving hemodynamic and clinical parameters, including pulmonary capillary wedge pressure, 6-min walking distance, and New York Heart Association functional class. Data on cardiovascular mortality and re-hospitalization for heart failure are still scarce.<\/jats:p>","DOI":"10.1007\/s10741-022-10280-4","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T21:17:42Z","timestamp":1668892662000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Device-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction"],"prefix":"10.1007","author":[{"given":"Mauro","family":"Riccardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Tomasoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Vizzardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6691-8568","authenticated-orcid":false,"given":"Marco","family":"Metra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"issue":"48","key":"10280_CR1","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1093\/eurheartj\/ehab670","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M et al (2021) Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 42(48):4901","journal-title":"Eur Heart J"},{"issue":"7","key":"10280_CR2","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ejhf.110","volume":"16","author":"EE van Riet","year":"2014","unstructured":"van Riet EE, Hoes AW, Limburg A, Landman MA, van der Hoeven H, Rutten FH (2014) Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail 16(7):772\u2013777","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10280_CR3","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.1002\/ehf2.13760","volume":"8","author":"L Stretti","year":"2021","unstructured":"Stretti L, Zippo D, Coats AJS, Anker MS, von Haehling S, Metra M et al (2021) A year in heart failure: an update of recent findings. ESC Heart Fail 8(6):4370\u20134393","journal-title":"ESC Heart Fail"},{"key":"10280_CR4","doi-asserted-by":"crossref","unstructured":"van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH (2016) Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 18(3):242\u201352","DOI":"10.1002\/ejhf.483"},{"issue":"3","key":"10280_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/ejhf.1741","volume":"22","author":"B Pieske","year":"2020","unstructured":"Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E et al (2020) How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 22(3):391\u2013412","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10280_CR6","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/ejhf.813","volume":"19","author":"O Chioncel","year":"2017","unstructured":"Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP et al (2017) Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19(12):1574\u20131585","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10280_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ejheart.2006.10.012","volume":"9","author":"EF Lewis","year":"2007","unstructured":"Lewis EF, Lamas GA, O\u2019Meara E, Granger CB, Dunlap ME, McKelvie RS et al (2007) Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail 9(1):83\u201391","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10280_CR8","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1161\/CIRCHEARTFAILURE.112.000216","volume":"6","author":"MR Zile","year":"2013","unstructured":"Zile MR, Kjellstrom B, Bennett T, Cho Y, Baicu CF, Aaron MF et al (2013) Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fraction. Circ Heart Fail 6(3):508\u2013516","journal-title":"Circ Heart Fail"},{"issue":"24","key":"10280_CR9","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1161\/CIRCULATIONAHA.108.815944","volume":"119","author":"DS Lee","year":"2009","unstructured":"Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ et al (2009) Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 119(24):3070\u20133077","journal-title":"Circulation"},{"issue":"6","key":"10280_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/eurjhf\/hft062","volume":"15","author":"MM Chan","year":"2013","unstructured":"Chan MM, Lam CS (2013) How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail 15(6):604\u2013613","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10280_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/eurheartj\/ehm554","volume":"29","author":"C Tribouilloy","year":"2008","unstructured":"Tribouilloy C, Rusinaru D, Mahjoub H, Souliere V, Levy F, Peltier M et al (2008) Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study. Eur Heart J 29(3):339\u2013347","journal-title":"Eur Heart J"},{"issue":"8","key":"10280_CR12","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","volume":"6","author":"CW Tsao","year":"2018","unstructured":"Tsao CW, Lyass A, Enserro D, Larson MG, Ho JE, Kizer JR et al (2018) Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail 6(8):678\u2013685","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10280_CR13","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","volume":"175","author":"Y Gerber","year":"2015","unstructured":"Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R et al (2015) A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 175(6):996\u20131004","journal-title":"JAMA Intern Med"},{"issue":"9386","key":"10280_CR14","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362(9386):777\u2013781","journal-title":"Lancet"},{"issue":"19","key":"10280_CR15","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JG Cleland","year":"2006","unstructured":"Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J et al (2006) The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27(19):2338\u20132345","journal-title":"Eur Heart J"},{"issue":"15","key":"10280_CR16","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383\u20131392","journal-title":"N Engl J Med"},{"issue":"23","key":"10280_CR17","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","volume":"53","author":"DJ van Veldhuisen","year":"2009","unstructured":"van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M et al (2009) Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 53(23):2150\u20132158","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10280_CR18","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","volume":"381","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al (2019) Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381(17):1609\u20131620","journal-title":"N Engl J Med"},{"issue":"23","key":"10280_CR19","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR et al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359(23):2456\u20132467","journal-title":"N Engl J Med"},{"issue":"5","key":"10280_CR20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1161\/CIRCULATIONAHA.106.628347","volume":"114","author":"A Ahmed","year":"2006","unstructured":"Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW et al (2006) Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary Digitalis Investigation Group trial. Circulation 114(5):397\u2013403","journal-title":"Circulation"},{"issue":"6","key":"10280_CR21","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/ehf2.12555","volume":"6","author":"D Tomasoni","year":"2019","unstructured":"Tomasoni D, Adamo M, Lombardi CM, Metra M (2019) Highlights in heart failure. ESC Heart Fail 6(6):1105\u20131127","journal-title":"ESC Heart Fail"},{"key":"10280_CR22","doi-asserted-by":"crossref","unstructured":"Tomasoni D, Adamo M, Anker MS, von Haehling S, Coats AJS, Metra M (2020) Heart failure in the last year: progress and perspective. ESC Heart Fail","DOI":"10.1002\/ehf2.13124"},{"issue":"3","key":"10280_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/ejhf.2397","volume":"24","author":"D Tomasoni","year":"2022","unstructured":"Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJS et al (2022) Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail 24(3):431\u2013441","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"10280_CR24","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461","journal-title":"N Engl J Med"},{"issue":"11","key":"10280_CR25","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","volume":"27","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, Kitzman DW, Shah SJ, Tang F et al (2021) The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med 27(11):1954\u20131960","journal-title":"Nat Med"},{"issue":"7","key":"10280_CR26","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.2249","volume":"23","author":"SD Solomon","year":"2021","unstructured":"Solomon SD, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN et al (2021) Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. Eur J Heart Fail 23(7):1217\u20131225","journal-title":"Eur J Heart Fail"},{"key":"10280_CR27","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med"},{"issue":"9","key":"10280_CR28","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jacc.2021.06.040","volume":"78","author":"M Fudim","year":"2021","unstructured":"Fudim M, Abraham WT, von Bardeleben RS, Lindenfeld J, Ponikowski PP, Salah HM et al (2021) Device therapy in chronic heart failure: JACC state-of-the-art review. J Am Coll Cardiol 78(9):931\u2013956","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10280_CR29","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jacc.2008.12.007","volume":"53","author":"MT Maeder","year":"2009","unstructured":"Maeder MT, Kaye DM (2009) Heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol 53(11):905\u2013918","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10280_CR30","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1056\/NEJMoa032566","volume":"350","author":"MR Zile","year":"2004","unstructured":"Zile MR, Baicu CF, Gaasch WH (2004) Diastolic heart failure\u2013abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 350(19):1953\u20131959","journal-title":"N Engl J Med"},{"issue":"9","key":"10280_CR31","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","volume":"11","author":"BA Borlaug","year":"2014","unstructured":"Borlaug BA (2014) The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 11(9):507\u2013515","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"10280_CR32","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1161\/CIRCULATIONAHA.117.032094","volume":"137","author":"T Feldman","year":"2018","unstructured":"Feldman T, Mauri L, Kahwash R, Litwin S, Ricciardi MJ, van der Harst P et al (2018) Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): a phase 2, randomized, sham-controlled trial. Circulation 137(4):364\u2013375","journal-title":"Circulation"},{"issue":"4","key":"10280_CR33","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/ejhf.976","volume":"20","author":"E Wolsk","year":"2018","unstructured":"Wolsk E, Kaye D, Borlaug BA, Burkhoff D, Kitzman DW, Komtebedde J et al (2018) Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 20(4):715\u2013722","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10280_CR34","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2459\/JCM.0000000000001366","volume":"23","author":"A Iacovoni","year":"2022","unstructured":"Iacovoni A, Palmieri V, Abete R, Vecchi AL, Mortara A, Gori M et al (2022) Right and left ventricular structures and functions in acute HFpEF: comparing the hypertensive pulmonary edema and worsening heart failure phenotypes. J Cardiovasc Med (Hagerstown) 23(10):663\u2013671","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"30","key":"10280_CR35","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1093\/eurheartj\/ehy301","volume":"39","author":"CSP Lam","year":"2018","unstructured":"Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ (2018) Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J 39(30):2780\u20132792","journal-title":"Eur Heart J"},{"issue":"44","key":"10280_CR36","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1093\/eurheartj\/ehu315","volume":"35","author":"S Dorfs","year":"2014","unstructured":"Dorfs S, Zeh W, Hochholzer W, Jander N, Kienzle RP, Pieske B et al (2014) Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. Eur Heart J 35(44):3103\u20133112","journal-title":"Eur Heart J"},{"issue":"6","key":"10280_CR37","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1161\/CIRCHEARTFAILURE.113.001229","volume":"7","author":"PB Adamson","year":"2014","unstructured":"Adamson PB, Abraham WT, Bourge RC, Costanzo MR, Hasan A, Yadav C et al (2014) Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail 7(6):935\u2013944","journal-title":"Circ Heart Fail"},{"issue":"8","key":"10280_CR38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006863","volume":"13","author":"DM Shavelle","year":"2020","unstructured":"Shavelle DM, Desai AS, Abraham WT, Bourge RC, Raval N, Rathman LD et al (2020) Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: one-year outcomes from the CardioMEMS post-approval study. Circ Heart Fail 13(8):e006863","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10280_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10741-019-09840-y","volume":"25","author":"E Gronda","year":"2020","unstructured":"Gronda E, Vanoli E, Zorzi A, Corrado D (2020) CardioMEMS, the real progress in heart failure home monitoring. Heart Fail Rev 25(1):93\u201398","journal-title":"Heart Fail Rev"},{"issue":"6","key":"10280_CR40","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/0002-9149(58)90264-9","volume":"2","author":"MP Sambhi","year":"1958","unstructured":"Sambhi MP, Zimmerman HA (1958) Pathologic physiology of Lutembacher syndrome. Am J Cardiol 2(6):681\u2013686","journal-title":"Am J Cardiol"},{"issue":"2","key":"10280_CR41","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/1522-726X(200102)52:2<177::AID-CCD1043>3.0.CO;2-G","volume":"52","author":"P Ewert","year":"2001","unstructured":"Ewert P, Berger F, Nagdyman N, Kretschmar O, Dittrich S, Abdul-Khaliq H et al (2001) Masked left ventricular restriction in elderly patients with atrial septal defects: a contraindication for closure? Catheter Cardiovasc Interv 52(2):177\u2013180","journal-title":"Catheter Cardiovasc Interv"},{"issue":"3","key":"10280_CR42","doi-asserted-by":"publisher","first-page":"309","DOI":"10.5603\/CJ.a2020.0077","volume":"27","author":"L Lewicki","year":"2020","unstructured":"Lewicki L, Sabiniewicz R, Siebert J, Szolkiewicz M (2020) Atrial flow regulator as a novel therapy for patients with chronic heart failure. Cardiol J 27(3):309\u2013311","journal-title":"Cardiol J"},{"issue":"6","key":"10280_CR43","doi-asserted-by":"publisher","first-page":"879","DOI":"10.5603\/CJ.a2020.0137","volume":"27","author":"L Lewicki","year":"2020","unstructured":"Lewicki L, Kosmalska K, Liedtke S, Karwowski M, Siebert J, Sabiniewicz R et al (2020) Pomeranian atRial flOw reguLatOr iN conGestive hEart failuRe (PROLONGER): study protocol. Cardiol J 27(6):879\u2013883","journal-title":"Cardiol J"},{"key":"10280_CR44","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3389\/fcvm.2019.00143","volume":"6","author":"DM Kaye","year":"2019","unstructured":"Kaye DM, Nanayakkara S (2019) Interatrial shunt device for heart failure with preserved ejection fraction. Front Cardiovasc Med 6:143","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"10280_CR45","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/ejhf.2184","volume":"23","author":"WT Abraham","year":"2021","unstructured":"Abraham WT (2021) Interatrial shunting for the treatment of heart failure: an on-demand, self-regulating left atrial pressure lowering system. Eur J Heart Fail 23(5):811\u2013813","journal-title":"Eur J Heart Fail"},{"issue":"9\u201310","key":"10280_CR46","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacbts.2021.06.002","volume":"6","author":"L Rosalia","year":"2021","unstructured":"Rosalia L, Ozturk C, Shoar S, Fan Y, Malone G, Cheema FH et al (2021) Device-based solutions to improve cardiac physiology and hemodynamics in heart failure with preserved ejection fraction. JACC Basic Transl Sci 6(9\u201310):772\u2013795","journal-title":"JACC Basic Transl Sci"},{"issue":"17","key":"10280_CR47","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016760","volume":"9","author":"JM Griffin","year":"2020","unstructured":"Griffin JM, Borlaug BA, Komtebedde J, Litwin SE, Shah SJ, Kaye DM et al (2020) Impact of interatrial shunts on invasive hemodynamics and exercise tolerance in patients with heart failure. J Am Heart Assoc 9(17):e016760","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10280_CR48","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4244\/EIJ-D-18-01211","volume":"15","author":"L Guimaraes","year":"2019","unstructured":"Guimaraes L, Lindenfeld J, Sandoval J, Bayes-Genis A, Bernier M, Provencher S et al (2019) Interatrial shunting for heart failure: current evidence and future perspectives. EuroIntervention 15(2):164\u2013171","journal-title":"EuroIntervention"},{"issue":"7","key":"10280_CR49","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/ejhf.111","volume":"16","author":"L Sondergaard","year":"2014","unstructured":"Sondergaard L, Reddy V, Kaye D, Malek F, Walton A, Mates M et al (2014) Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail 16(7):796\u2013801","journal-title":"Eur J Heart Fail"},{"key":"10280_CR50","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ijcard.2015.03.198","volume":"187","author":"F Malek","year":"2015","unstructured":"Malek F, Neuzil P, Gustafsson F, Kaye DM, Walton A, Mates M et al (2015) Clinical outcome of transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel implant. Int J Cardiol 187:227\u2013228","journal-title":"Int J Cardiol"},{"issue":"10025","key":"10280_CR51","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/S0140-6736(16)00704-2","volume":"387","author":"G Hasenfuss","year":"2016","unstructured":"Hasenfuss G, Hayward C, Burkhoff D, Silvestry FE, McKenzie S, Gustafsson F et al (2016) A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet 387(10025):1298\u20131304","journal-title":"Lancet"},{"key":"10280_CR52","doi-asserted-by":"crossref","unstructured":"Kaye DM, Hasenfuss G, Neuzil P, Post MC, Doughty R, Trochu JN et al (2016) One-year outcomes after transcatheter insertion of an interatrial shunt device for the management of heart failure with preserved ejection fraction. Circ Heart Fail 9(12)","DOI":"10.1161\/CIRCHEARTFAILURE.116.003662"},{"issue":"1","key":"10280_CR53","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ehf2.12350","volume":"6","author":"DM Kaye","year":"2019","unstructured":"Kaye DM, Petrie MC, McKenzie S, Hasenfubeta G, Malek F, Post M et al (2019) Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. ESC Heart Fail 6(1):62\u201369","journal-title":"ESC Heart Fail"},{"issue":"10330","key":"10280_CR54","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/S0140-6736(22)00016-2","volume":"399","author":"SJ Shah","year":"2022","unstructured":"Shah SJ, Borlaug BA, Chung ES, Cutlip DE, Debonnaire P, Fail PS et al (2022) Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. Lancet 399(10330):1130\u20131140","journal-title":"Lancet"},{"issue":"9","key":"10280_CR55","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.4244\/EIJY14M05_07","volume":"10","author":"IJ Amat-Santos","year":"2015","unstructured":"Amat-Santos IJ, Bergeron S, Bernier M, Allende R, Barbosa Ribeiro H, Urena M et al (2015) Left atrial decompression through unidirectional left-to-right interatrial shunt for the treatment of left heart failure: first-in-man experience with the V-Wave device. EuroIntervention 10(9):1127\u20131131","journal-title":"EuroIntervention"},{"issue":"10025","key":"10280_CR56","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S0140-6736(16)00585-7","volume":"387","author":"M Del Trigo","year":"2016","unstructured":"Del Trigo M, Bergeron S, Bernier M, Amat-Santos IJ, Puri R, Campelo-Parada F et al (2016) Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-of-principle cohort study. Lancet 387(10025):1290\u20131297","journal-title":"Lancet"},{"issue":"22","key":"10280_CR57","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.jcin.2018.07.001","volume":"11","author":"J Rodes-Cabau","year":"2018","unstructured":"Rodes-Cabau J, Bernier M, Amat-Santos IJ, Ben Gal T, Nombela-Franco L, Garcia Del Blanco B et al (2018) Interatrial shunting for heart failure: early and late results from the first-in-human experience with the V-Wave system. JACC Cardiovasc Interv 11(22):2300\u20132310","journal-title":"JACC Cardiovasc Interv"},{"issue":"16","key":"10280_CR58","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.4244\/EIJ-D-19-00291","volume":"15","author":"L Guimaraes","year":"2020","unstructured":"Guimaraes L, Bergeron S, Bernier M, Rodriguez-Gabella T, Del Val D, Pibarot P et al (2020) Interatrial shunt with the second-generation V-Wave system for patients with advanced chronic heart failure. EuroIntervention 15(16):1426\u20131428","journal-title":"EuroIntervention"},{"issue":"6","key":"10280_CR59","doi-asserted-by":"publisher","first-page":"706","DOI":"10.4244\/EIJY15M07_08","volume":"11","author":"MB Patel","year":"2015","unstructured":"Patel MB, Samuel BP, Girgis RE, Parlmer MA, Vettukattil JJ (2015) Implantable atrial flow regulator for severe, irreversible pulmonary arterial hypertension. EuroIntervention 11(6):706\u2013709","journal-title":"EuroIntervention"},{"issue":"1","key":"10280_CR60","doi-asserted-by":"publisher","first-page":"204589402198996","DOI":"10.1177\/2045894021989966","volume":"11","author":"K Sivakumar","year":"2021","unstructured":"Sivakumar K, Rohitraj GR, Rajendran M, Thivianathan N (2021) Study of the effect of occlutech atrial flow regulator on symptoms, hemodynamics, and echocardiographic parameters in advanced pulmonary arterial hypertension. Pulm Circ 11(1):2045894021989966","journal-title":"Pulm Circ"},{"issue":"5","key":"10280_CR61","doi-asserted-by":"publisher","first-page":"403","DOI":"10.4244\/EIJ-D-19-00342","volume":"15","author":"C Paitazoglou","year":"2019","unstructured":"Paitazoglou C, Ozdemir R, Pfister R, Bergmann MW, Bartunek J, Kilic T et al (2019) The AFR-PRELIEVE trial: a prospective, non-randomised, pilot study to assess the atrial flow regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction. EuroIntervention 15(5):403\u2013410","journal-title":"EuroIntervention"},{"issue":"40","key":"10280_CR62","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E et al (2019) How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 40(40):3297\u20133317","journal-title":"Eur Heart J"},{"issue":"5","key":"10280_CR63","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/ejhf.2119","volume":"23","author":"C Paitazoglou","year":"2021","unstructured":"Paitazoglou C, Bergmann MW, Ozdemir R, Pfister R, Bartunek J, Kilic T et al (2021) One-year results of the first-in-man study investigating the atrial flow regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study. Eur J Heart Fail 23(5):800\u2013810","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10280_CR64","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/ejhf.2360","volume":"23","author":"L Lauder","year":"2021","unstructured":"Lauder L, Pereira TV, Degenhardt MC, Ewen S, Kulenthiran S, Coats AJS et al (2021) Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta-analysis. Eur J Heart Fail 23(11):1960\u20131970","journal-title":"Eur J Heart Fail"},{"key":"10280_CR65","doi-asserted-by":"crossref","unstructured":"Simard T, Labinaz M, Zahr F, Nazer B, Gray W, Hermiller J et al (2020) Percutaneous atriotomy for levoatrial-to-coronary sinus shunting in symptomatic heart failure: first-in-human experience. Jacc Cardiovasc Interv 13(10):1236\u201347","DOI":"10.1016\/j.jcin.2020.02.022"},{"issue":"10","key":"10280_CR66","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.jcin.2020.03.036","volume":"13","author":"F Mahfoud","year":"2020","unstructured":"Mahfoud F, Ewen S, Kulenthiran S (2020) Levoatrial-to-coronary sinus shunting in heart failure therapy: getting off the beaten track? JACC Cardiovasc Interv 13(10):1248\u20131250","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"10280_CR67","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008362","volume":"15","author":"W Sun","year":"2022","unstructured":"Sun W, Zou H, Yong Y, Liu B, Zhang H, Lu J et al (2022) The RAISE Trial: a novel device and first-in-man trial. Circ Heart Fail 15(4):e008362","journal-title":"Circ Heart Fail"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-022-10280-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-022-10280-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-022-10280-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T08:17:06Z","timestamp":1669018626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-022-10280-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"references-count":67,"alternative-id":["10280"],"URL":"https:\/\/doi.org\/10.1007\/s10741-022-10280-4","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"5 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"M.M. reports fees from Actelion, Amgen, AstraZeneca, Livanova, Servier, Vifor Pharma, and Windtree Therapeutics as a member of clinical trial committees or advisory boards and from Abbott Vascular, Bayer, Boehringer Ingelheim, and Edwards Therapeutics for speeches at sponsored meetings in the last 3\u00a0years. M.A. reports speaker fees from Abbott Vascular and Medtronic. M.R, D.T., and E.V. have nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}